I-Pembrolizumab Yamkelwe eTshayina kwi-HCC Engasuswayo xa idityaniswe neLenvatinib kunye ne-TACE

Kutshanje, iMerck & Co., Inc. (Merck) ibhengeze ukuba i-PD-1 inhibitor yayo, i-pembrolizumab, ivunyiwe yiNational Medical Products Administration (NMPA) yaseTshayina ukuba isetyenziswe kunye ne-lenvatinib kunye ne-transarterial chemoembolization (TACE) kunyango lwezigulane ezine-carcinoma ye-hepatocellular engasuswayo, engeyiyo i-metastatic.

Ukuvunywa kwesi sibonakaliso sitsha kusekelwe kwidatha evela kuvavanyo lweklinikhi lweSigaba sesiThathu se-LEAP-012. Kolu phononongo lweSigaba sesiThathu oluneziko ezininzi, olucwangcisiweyo, olungaboni kabini, (LEAP-012), izigulane ezingama-480 zabhaliswa kwaye zabelwa ngokungacwangciswanga ukuba zifumane i-lenvatinib kunye ne-TACE kunye ne-pembrolizumab (n=237) okanye i-TACE kunye ne-dual placebo (n=243).

Iziphumo zibonise ukuba i-median progression-free survival (PFS) yayiyi-14.6 iinyanga kwiqela le-lenvatinib kunye ne-TACE kunye ne-pembrolizumab, xa kuthelekiswa ne-10.0 iinyanga kwiqela le-placebo. Amazinga okusinda kweenyanga ezingama-24 (OS) ayeyi-75% kunye ne-69%, ngokwahlukeneyo.

I-Lenvatinibsisithinteli se-kinase esisetyenziselwa ukunyanga iintlobo ezithile zomhlaza. Izithinteli ze-Kinase zizithinteli ze-enzyme ezithintela ukusebenza kwe-protein kinase enye okanye ezingaphezulu.

I-Pembrolizumab yi-antibody ye-monoclonal IgG4 kappa eyenziwe ngumntu ejoliswe kumphezulu weseli yomntu i-PD-1 (i-programmed death receptor-1) kwi-lymphocytes. I-PD-1 receptor inika "indawo yokujonga amasosha omzimba" ebalulekileyo, enceda ekuthinteleni inkqubo yomzimba yokuzikhusela ekuzihlaseleni. Iindidi ezithile zeethumba zine-PD-L1 ephezulu (i-programmed death receptor ligand-1). Ezinye iintlobo zeethumba zisebenzisa ukumelana nokuzikhusela komzimba okuguquguqukayo apho zithatha i-physiology yendalo ye-PD-L1 induction (ukukhuselwa komonakalo obangelwa kukuzikhusela komzimba kwiintsholongwane) kwaye ziyilungelelanise neempendulo zokulwa nethumba. Xa i-PD-L1 idibana ne-PD-1, umsebenzi we-T-cell uyathinteleka; i-pembrolizumab ivimba ukwakheka kwe-PD-1: PDL-1 complex evumela ukubulawa okuphuculweyo okubangelwa kukusetyenziswa kwe-T-cell.

Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.

Inombolo yefowuni: 4008803716

Email：myimmnet@163.com